Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (560)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT07658586 | AI Multimodal Model for Liver Cancer Diagnosis and Prognosis(AIM-LCAP) | active not recruiting | — | 600 | Guangxi Medical UniversityOTHER | 1 |
| Jul 1, 2026 |
| clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05557838 | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC(TREMENDOUS) | active not recruiting | Phase 3 | 214 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07669597 | Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag(HCC) | active not recruiting | — | 50 | Sohag Oncology CenterOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02156739 | Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions | active not recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT03991832 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors(SOLID) | active not recruiting | Phase 2 | 58 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02151084 | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | active not recruiting | Phase 2 | 57 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04727307 | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial(AB-LATE02) | active not recruiting | Phase 2 | 202 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658105 | Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI(Ad-rHCC) | active not recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07654530 | Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.(SIAG-BTC) | active not recruiting | Phase 2 | 107 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01787409 | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | active not recruiting | N/A | 565 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05038254 | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | active not recruiting | N/A | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04367805 | COVID-19 Infection in Patients With Hepatocellular Carcinoma(COVID19-CHIEF) | active not recruiting | — | 23 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07646717 | Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma(LPHAIC for ICC) | active not recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07645209 | A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions | active not recruiting | — | 1,000 | Harbin Medical UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 1 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06204159 | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery(Trinav) | active not recruiting | N/A | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07466225 | HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion | active not recruiting | — | 150 | Peking UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635290 | Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 26 | West China HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07444905 | Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma | active not recruiting | — | 1,523 | Tongji HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03801083 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | active not recruiting | Phase 2 | 4 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05507632 | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 48 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02757859 | WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer | active not recruiting | N/A | 845 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06465563 | SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 93 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07613125 | The Effect of Locally Made Nutritional Supplementation on Cancer Cachexia in Bangladesh: A Quasi-experimental Study. | active not recruiting | N/A | 106 | International Centre for Diarrhoeal Disease Research, BangladeshOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03896646 | Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) | active not recruiting | N/A | 42 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04196465 | Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(NeoChance) | active not recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05546879 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC(Liver-NET1) | active not recruiting | Phase 1 | 43 | University Hospital, GrenobleOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02984566 | Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)(TROG1703 LARK) | active not recruiting | N/A | 32 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | active not recruiting | Phase 2 | 32 | Academic and Community Cancer Research UnitedOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07581769 | Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging | active not recruiting | — | 500 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT07081633 | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma(TREMENDOUS-2) | active not recruiting | Phase 2 | 114 | AstraZenecaINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06519721 | Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC | active not recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07138885 | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma(DRIVE-II) | active not recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03631173 | Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy(MINIMUM) | active not recruiting | N/A | 201 | Oslo University HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 1, 2026source: clinicaltrials